FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590093135> ?p ?o ?g. }

• W2590093135 endingPage "450" @default.
• W2590093135 startingPage "450" @default.
• W2590093135 abstract "450 Background: Pazopanib is a VEGF receptor inhibitor active in the treatment of advanced RCC treatment, and Interferon has been a long-standing treatment option for metastatic RCC with a modest overall survival benefit. The purpose of this study is to assess the feasibility and safety of the combination of pazopanib and interferon in the treatment of advanced RCC and other tumor types. Methods: This is a phase I study of the combination of pazopanib and interferon alfa-2A. It has been developed in a 3+3 standard escalating design with cohorts of 3-6 patients (pts) to identify the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended dose (RD). Pazopanib is given po daily and interferon is given subcutaneously 3 times a week. Dose levels 1, 2, 3, 4 and 5 corresponded to pazopanib 400, 600, 800, 800 and 800 mg per day plus interferon 3, 3, 3, 6 and 9 million U. Patients with previously treated RCC and also other primary tumors could be included. Results: 19 pts were included and treated in 4 dose levels. Patients’ median age was 60 years old, 13 men and 6 women. Six of them were diagnosed with RCC; other pts presented metastatic tumors as ovarian carcinoma, peritoneal mesothelioma, breast cancer (2), liposarcoma, breast angiosarcoma, uterine sarcomas (3), endometrial carcinoma (3) and melanoma. MTD was reached at level 4, and the RD was Pazopanib 800mg with IFN 3MUI. Three pts experienced DLT, one in level 2 and two in level 4: grade 4 transaminitis, grade 3 transaminitis and grade 3 liver hematoma, respectively. Other toxicities (grade 3 and 4) included anemia, neutropenia, thrombocytopenia, asthenia, arthromialgia, anorexia, diarrhea and Raynaud’s syndrome. Additional mild but common toxicities were fever and proteinuria. One partial response was observed in a uterine sarcoma patient. In RCC, 4 pts achieved stable disease lasting a median of 5 cycles. Conclusions: Combination of pazopanib and interferon alfa is feasible and safe, allowing administration of active doses of both agents. A phase II study to assess this combination activity in RCC is assured. Clinical trial information: NCT01513187." @default.
• W2590093135 created "2017-03-03" @default.
• W2590093135 creator A5004741487 @default.
• W2590093135 creator A5036620887 @default.
• W2590093135 creator A5041173579 @default.
• W2590093135 creator A5055824195 @default.
• W2590093135 creator A5069482220 @default.
• W2590093135 date "2014-02-01" @default.
• W2590093135 modified "2023-10-06" @default.
• W2590093135 title "Phase I study of pazopanib in combination with interferon alfa in patients with advanced renal cell carcinoma (RCC) and other primary tumors: A Spanish Oncology Genitourinary Group (SOGUG) study." @default.
• W2590093135 doi "https://doi.org/10.1200/jco.2014.32.4_suppl.450" @default.
• W2590093135 hasPublicationYear "2014" @default.
• W2590093135 type Work @default.
• W2590093135 sameAs 2590093135 @default.
• W2590093135 citedByCount "0" @default.
• W2590093135 crossrefType "journal-article" @default.
• W2590093135 hasAuthorship W2590093135A5004741487 @default.
• W2590093135 hasAuthorship W2590093135A5036620887 @default.
• W2590093135 hasAuthorship W2590093135A5041173579 @default.
• W2590093135 hasAuthorship W2590093135A5055824195 @default.
• W2590093135 hasAuthorship W2590093135A5069482220 @default.
• W2590093135 hasConcept C126322002 @default.
• W2590093135 hasConcept C126894567 @default.
• W2590093135 hasConcept C143998085 @default.
• W2590093135 hasConcept C2776539811 @default.
• W2590093135 hasConcept C2777472916 @default.
• W2590093135 hasConcept C2778439243 @default.
• W2590093135 hasConcept C2779490328 @default.
• W2590093135 hasConcept C2781068499 @default.
• W2590093135 hasConcept C71924100 @default.
• W2590093135 hasConceptScore W2590093135C126322002 @default.
• W2590093135 hasConceptScore W2590093135C126894567 @default.
• W2590093135 hasConceptScore W2590093135C143998085 @default.
• W2590093135 hasConceptScore W2590093135C2776539811 @default.
• W2590093135 hasConceptScore W2590093135C2777472916 @default.
• W2590093135 hasConceptScore W2590093135C2778439243 @default.
• W2590093135 hasConceptScore W2590093135C2779490328 @default.
• W2590093135 hasConceptScore W2590093135C2781068499 @default.
• W2590093135 hasConceptScore W2590093135C71924100 @default.
• W2590093135 hasIssue "4_suppl" @default.
• W2590093135 hasLocation W25900931351 @default.
• W2590093135 hasOpenAccess W2590093135 @default.
• W2590093135 hasPrimaryLocation W25900931351 @default.
• W2590093135 hasRelatedWork W2010432240 @default.
• W2590093135 hasRelatedWork W2056454490 @default.
• W2590093135 hasRelatedWork W2063526820 @default.
• W2590093135 hasRelatedWork W2726542547 @default.
• W2590093135 hasRelatedWork W2816965188 @default.
• W2590093135 hasRelatedWork W2899094668 @default.
• W2590093135 hasRelatedWork W2970863592 @default.
• W2590093135 hasRelatedWork W3080833635 @default.
• W2590093135 hasRelatedWork W4200482748 @default.
• W2590093135 hasRelatedWork W4226147939 @default.
• W2590093135 hasVolume "32" @default.
• W2590093135 isParatext "false" @default.
• W2590093135 isRetracted "false" @default.
• W2590093135 magId "2590093135" @default.
• W2590093135 workType "article" @default.